The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase II study of biweekly paclitaxel and S-1 (SPA) as first-line combination therapy in patients with metastatic or locally advanced gastric cancer.
Haiping Jiang
No relevant relationships to disclose
Yulong Zheng
No relevant relationships to disclose
Jiong Qian
No relevant relationships to disclose
Xiaochen Zhang
No relevant relationships to disclose
Haibo Mou
No relevant relationships to disclose
Peng Zhao
No relevant relationships to disclose
Chenyu Mao
No relevant relationships to disclose
Yi Zheng
No relevant relationships to disclose
Yao Wang
No relevant relationships to disclose
Lan Fang Yu
No relevant relationships to disclose
Jing Deng
No relevant relationships to disclose
Weijiang Fang
No relevant relationships to disclose
Nong Xu
No relevant relationships to disclose